A strategy for the selective removal of mri contrast agents
AssigneePortland State University
InventorsMark Woods, Karley B. Maier
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method for removing contract agents, such as a gadolinium-based contrast agent, from a liquid. The contract agent may comprise a bioorthogonal reaction pair moiety and the method may comprise contacting a solid support that comprises a complementary bioorthogonal reaction pair moiety with the liquid. In some embodiments, the liquid comprises urine or blood.
Claims21
1-23. (canceled)
A method, comprising contacting a solid support comprising a first bioorthogonal reaction pair moiety with a liquid comprising a contrast agent comprising a second bioorthogonal reaction pair moiety that is complementary to the first bioorthogonal reaction pair moiety.
A method, comprising contacting a solid support comprising a first bioorthogonal reaction pair moiety with a liquid comprising a contrast agent comprising a second bioorthogonal reaction pair moiety that is complementary to the first bioorthogonal reaction pair moiety, thereby linking the contrast agent to the solid support;
- and
- separating the contrast agent from the liquid by eluting the liquid from the solid support.
A compound having a structure according to any one of Formulas V-A to VIII-C
- wherein
- each R1 independently is R or —L—BG, where at least one R1 is —L—BG;
- each R independently is H, aliphatic, or aryl;
- L is a bond, —C1-6alkyl-, —C1-6alkyl-C(O)—, —O—C1-6alkyl-, —O—C1-6alkyl-C(O)—, —NHC1-6alkyl-, or —NHC1-6alkylC(O)—;
- BG is a bioorthogonal reaction pair moiety;
- R2 is selected from
- M is selected from Gd3+, Mn2+ or Fe3+
- dotted lines “” indicate an optional bond from the metal M to a nitrogen atom;
- dashed lines “” indicate one or two optional bonds from the metal M to an R2 substituent;
- and
- the contrast agent comprises at least five of the optional dotted and/or dashed bonds.
Dependencies are inferred from the claim text.